^
    Back
    Association details:
    Biomarker:PIK3R1 EY451delinsD
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Mol Biol Rep
    Title:

    A novel mutant PIK3R1 EY451delinsD breast cancer patient resistant to HER2-targeted therapy treated with everolimus: a case report

    Published date:
    04/06/2022
    Excerpt:
    We present a case of a HER2-positive advanced breast cancer patient with the PIK3R1EY451delinsD mutation who developed resistance to HER2-targeted therapy and had a better response to everolimus combined with trastuzumab and carboplatin.
    Secondary therapy:
    carboplatin
    DOI:
    10.1007/s11033-022-07407-z